{"entity":{"id":"nct05190445","kind":"trial","name":"Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma","aka":[],"tldr":"A phase 2 trial of Cinrebafusp alfa, Ramucirumab and Tucatinib in gastric & gastro-oesophageal junction cancer, run by Pieris Pharmaceuticals, Inc., active and no longer recruiting.","summary":"Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma is a phase 2 interventional study registered as NCT05190445 by Pieris Pharmaceuticals, Inc., with 80 participants enrolled, started 2021-11-01 and due to reach its primary completion in 2023-02-01. Interventions recorded: Cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel and Cinrebafusp alfa (PRS-343) in combination with tucatinib.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05190445","url":"https://clinicaltrials.gov/study/NCT05190445"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric"],"sections":[],"technologies":["antiangiogenic","her2-tyrosine-kinase-inhibitors","kinase-inhibitors","monoclonal-antibody"],"targets":[],"drugs":["cinrebafusp-alfa","ramucirumab","tucatinib"],"companies":["pieris-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05190445","phase":"2","setting":"A Phase 2, Multi-Center, Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination With Ramucirumab and Paclitaxel in Patients With HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination With Tucatinib in Patients With HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma","sponsor":"Pieris Pharmaceuticals, Inc.","started":"2021-11-01","startedType":"actual","enrolled":80,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05190445/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"her2-tyrosine-kinase-inhibitors","kind":"technology","name":"HER2 tyrosine kinase inhibitors","route":"/technologies/her2-tyrosine-kinase-inhibitors/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"cinrebafusp-alfa","kind":"drug","name":"Cinrebafusp alfa","route":"/drugs/cinrebafusp-alfa/"},{"id":"ramucirumab","kind":"drug","name":"Ramucirumab","route":"/drugs/ramucirumab/"},{"id":"tucatinib","kind":"drug","name":"Tucatinib","route":"/drugs/tucatinib/"}],"company":[{"id":"pieris-pharmaceuticals","kind":"company","name":"Pieris Pharmaceuticals","route":"/companies/pieris-pharmaceuticals/"}]}}